The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study. by Wu, Qianhui et al.
RESEARCH ARTICLE
The economic burden of cervical cancer from
diagnosis to one year after final discharge in
Henan Province, China: A retrospective case
series study
Qianhui Wu1, Manman Jia2, Hongmin Chen2, Shaokai Zhang2, Yang Liu3, Kiesha Prem3,
Mengcen Qian1,4*, Hongjie YuID1,5*
1 School of Public Health, Fudan University, Shanghai, China, 2 Henan Cancer Hospital, Affiliated Cancer
Hospital of Zhengzhou University, Zhengzhou, China, 3 Department of Infectious Disease Epidemiology,
London School of Hygiene and Tropical Medicine, London, England, United Kingdom, 4 Key Laboratory
Health Technology Assessment (Fudan University), Ministry of Health, Shanghai, China, 5 Key Laboratory of
Public Health Safety (Fudan University), Ministry of Education, Shanghai, China
* qianmengcen@fudan.edu.cn (MQ); yhj@fudan.edu.cn (HY)
Abstract
Background
In China, the disease burden of cervical cancer remains substantial. Human papillomavirus
(HPV) vaccines are expensive and not yet centrally funded. To inform immunization policy,
understanding the economic burden of the disease is necessary. This study adopted a soci-
etal perspective and investigated costs and quality of life changes associated with cervical
cancer from diagnosis to one year after final discharge in Henan province, China.
Methods
Inpatient records of cervical cancer patients admitted to the largest cancer hospital in Henan
province between Jan. 2017 and Dec. 2018 were extracted. A telephone interview with four
modules was conducted in Jun.-Jul. 2019 with a 40% random draw of patients to obtain
direct non-medical costs and indirect costs associated with inpatients, costs associated with
outpatient visits, and changes in quality of life status using the EQ-5D-5L instrument. Direct
medical expenditures were converted to opportunity costs of care using cost-to-charge
ratios obtained from hospital financial reports. For each clinical stage (IA-IV), total costs per
case from diagnosis to one year after final discharge were extrapolated based on inpatient
records, responses to the telephone interview, and recommendation on outpatient follow-
ups by Chinese cervical cancer treatment guidelines. Loss in quality-adjusted life years was
obtained using the ‘under the curve’ method and regression predictions.
Results
A total of 3,506 inpatient records from 1,323 patients were obtained. Among 541 randomly
selected patients, 309 completed at least one module of the telephone interview. The aver-
age total costs per case associated with cervical cancer from diagnosis to one year after
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final discharge ranged from $8,066-$22,888 (in 2018 US Dollar) and the quality-adjusted life
years loss varied from 0.05–0.26 for IA-IV patients.
Conclusions
The economic burden associated with cervical cancer is substantial in Henan province. Our
study provided important baseline information for cost-effectiveness analysis of HPV immu-
nization program in China.
1. Introduction
The disease burden of cervical cancer has been substantial globally, especially for less devel-
oped regions. In 2018, there were approximately 570,000 new cases and 311,000 cervical cancer
related deaths, more than 84% of which were from low- and middle-income countries (LMIC)
[1]. In China, cervical cancer is the second most common female malignancy and a leading
cause of cancer-related death among women. It is estimated that in 2015 cervical cancer caused
30,500 deaths and recorded 98,900 new cases [2]. From 2000 to 2014, crude incidence rates of
cervical cancer increased by 10% and 12.5% annually in urban and rural China, respectively
[3].
Persistent human papillomavirus (HPV) infection is a necessary cause of cervical cancer
[4]. If left undetected or untreated for years or decades, cervical intraepithelial neoplasia may
progress to cervical cancer [5]. Fortunately, prophylactic vaccines that can effectively prevent
HPV infections have been licensed in many countries throughout the world, including China.
To eliminate cervical cancer globally, the World Health Organization recommends HPV vac-
cination for all adolescent girls aged between 9–14 years as the primary target population and,
if proved to be cost-effective, older females or males as the secondary target populations [6].
However, HPV vaccines are not currently centrally funded in China–individuals have to
pay the full amount of the shots out-of-pocket. The total costs of three doses of HPV vaccines
are $140-$444 (depending on the choice of vaccine and including the newly approved domes-
tic bivalent HPV vaccine), corresponding to around 3.3% to 10.4% of the annual disposable
income per capita in China as of 2018, which is very expensive for most to afford. To support
the decision of introducing HPV vaccines into China’s National Immunization Programme,
evidence based on cost-effectiveness analyses is necessary. Estimates of economic burden of
cervical cancer in China provide important baseline data for such analyses.
Following up cervical cancer patients prospectively over the entire treatment process since
diagnosis is an ideal study design. However, it is hard to implement due to the long treatment
duration of cancers. Previous studies that examined economic costs associated with cervical
cancer in China mainly adopted a hospital-based design and focused solely on total medical
expenditures of inpatient stays [7–9]. Shi et al. and Liu et al. are two notable exceptions–they
examined the direct costs of cervical cancer screening, diagnosis, and treatment using a micro-
costing approach based on clinical pathways [10, 11]. However, the treatment process of cervi-
cal cancer can be complicated and include multiple inpatient admissions. Income losses and
transportation costs associated with the disease also aggravate household-level financial bur-
den. Moreover, although researchers have explored the health related quality of life (HRQoL)
status of cervical cancer patients [12–14], the loss in quality-adjusted life years (QALY) associ-
ated with the disease in China is less well understood.
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In this study, we adopted a societal perspective, extracted inpatient records, and conducted
a retrospective telephone survey among cervical cancer patients who attended the largest can-
cer hospital in Henan province to estimate the economic burden of cervical cancer. We con-
sidered both direct and indirect costs from diagnosis to one year after final discharge. We also
assessed the quality of life impact of cervical cancer using QALY loss.
2. Material and methods
2.1. Study design and patient enrollment
Henan province is located in central China, with a per-capita GDP level ranking the 18th out
of all 31 provinces in 2017. During 2011–2015, the central region of China accounted for 31%
of total hospitalization expenditures for tumor treatment across the country, and specialized
cancer hospitals amounted to 50% of the total [15]. The study hospital, Henan Cancer Hospi-
tal, is located in the capital city of Henan province. It is the largest hospital specializing in
tumor treatment in the city and attracts a large number of patients with cervical diseases from
surrounding areas.
Patients who were admitted to the Gynecology Department at Henan Cancer Hospital
between January 1, 2017 and December 31, 2018 were considered the potential participants of
this study. Fig 1 provides an overview of the data collection and analytical processes. The left
half of Fig 1 presents the patient enrollment procedure. Records of inpatient episodes from
hospital information system for patients who met with the following inclusion criteria were
extracted: (1) aged 18 years or above, (2) had been histologically confirmed of cervical cancer
(ICD-10-C53), (3) had identified a definite clinical stage (IA-IV), (4) had received at least one
type of treatment (i.e. surgery, radiotherapy, chemotherapy, or any two or three combination
of the above) during hospitalization, (5) had no other cancers or precancerous conditions, and
(6) were not patients with cancer relapse. These inpatient records contained clinical character-
istics and medical expenditures (also referred to hospital charges, the total amount paid by the
patients and the insurer) as well as demographic information of the patients.
Then, patients who completed inpatient treatment and were recommended for regular out-
patient follow-ups were identified based on discharge summaries. Information on the entire
treatment process of the patients was obtained based on treatment history on their last
observed inpatient records.
Finally, a 40% random sample without replacement of all patients with inpatient records
were invited to a telephone survey, where information on socioeconomic characteristics (edu-
cation level and monthly family income) were collected. Patients were asked to recall costs
associated with cervical cancer from diagnosis to the interview day and changes in quality of
life states.
2.2. Telephone survey
The telephone survey was conducted between June 3, 2019 and July 25, 2019 by LinkDoc, a
company specializes in patient follow-ups in China. Staffs from LinkDoc were trained and
supervised by the research investigators. A computer-assisted telephone interviewing system
was used to record answers directly into a computer. A patient was classified as unreachable if
we failed to get in touch with her after four attempts made on different days. After verbal con-
sents from the participants, demographic and clinical information was verified using their
most recent inpatient records.
There were four modules in the survey. Accordingly, four samples were generated based on
complete responses to each module. First, the EQ-5D-5L instrument was used to assess the
health states of the patients. EQ-5D is a standardized five-dimensional preference-based
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health-related quality of life questionnaire designed by the EuroQol Group, which consists of a
descriptive system with five dimensions and a visual analogue scale (VAS). The instrument has
been validated in China and among cervical cancer patients in Asian populations [16, 17].
Patients were asked to report their self-rated level of health on the interview day and the day
that they felt the worst since diagnosis to the interview day.
Second, non-medical costs associated with inpatient episodes were collected. Average direct
non-medical costs (i.e. costs of transportation, accommodation, additional nutrients and nurs-
ing incurred to patients and their caregivers) and indirect costs (income losses incurred to the
patients and caregivers) associated with each inpatient episode were obtained. For respondents
who could not provide a detailed value for income loss, changes in employment status and loss
of work days associated with inpatient episodes were asked and used as proxies.
Third, average direct medical expenditures (including both out-of-pocket and reimbursable
portions) associated with each outpatient visit were obtained. Fourth, average direct non-med-
ical costs associated with each outpatient visit were acquired. Average indirect costs associated
with outpatient visits were not collected because most participants thought the amount was
trivial. Indirect costs due to productivity loss and premature death were not considered.
Fig 1. Conceptual diagram of data collection and analysis processes. After inclusion criteria were applied, patients experienced final discharges were identified
(n = 844) and then a 40% random sample of all eligible patients was drawn. The two samples that labelled with � contained overlapping patients. During the telephone
survey, samples were generated based on complete responses to each module. The four samples that labelled with �� also contained overlapping patients.
https://doi.org/10.1371/journal.pone.0232129.g001
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2.3. Data analysis
The right half of Fig 1 summarizes the data analytical process. In China, prices of drug and
healthcare services at public hospitals are determined by the government. Accordingly, medi-
cal expenditures may well represent the financial burden that incur to households and health
insurance payers, but are not necessarily matched with costs incurred to hospitals [18]. Unfor-
tunately, accurate estimates of cost-to-charge ratios for specific healthcare services provided by
hospitals in China are not currently available. To address this issue, the average cost-to-charge
ratio (0.925) of the study hospital during 2017–2018 was obtained from its annual financial
reports. Direct medical expenditures were converted into opportunity costs of care to the
study hospital using this ratio.
From the responses provided by patients who completed the inpatient module during the
telephone survey, costs per inpatient episode were calculated by adding up the direct medical
costs, the direct non-medical costs, and the indirect costs. Generalized linear regression mod-
els (GLM) were used to identify predictors of costs. Demographic, socioeconomic, and clinical
characteristics and treatment methods were investigated.
Then, total costs per case by clinical stages from diagnosis to one year after final discharge
were extrapolated. The treatment processes were broadly divided into two phases: the inpatient
phase (from diagnosis to final discharge) and the outpatient phase (one year after final
discharge).
For the inpatient phase, direct medical costs were calculated based on two parameters: first,
the average direct medical costs associated with inpatient episodes, which were estimated by
treatment type using all eligible inpatient records; and second, the average number of hospital-
ization, which was estimated by treatment type received during the entire inpatient phase
using only records of patients who experienced final discharge. Using the group of patients
with IA cervical cancer as an example: there were 37 patients who experienced final discharge,
36 of whom were hospitalized once for surgery, and one patient for five times (once for sur-
gery, and the other four for chemotherapy). Therefore, the average number of hospitalization
with surgery and chemotherapy received per IA patient was 1 (37/37) and 0.11 (4/37), respec-
tively. Direct medical costs were calculated by multiplying the aforementioned parameters for
each treatment type and then adding up their products for each clinical stage. Direct non-med-
ical costs and indirect costs were calculated by multiplying the average of the two costs associ-
ated with each inpatient episode with the average number of hospitalizations during the
inpatient phase. If the respondents provided an un-useable answer to indirect costs, their cor-
responding estimates were derived using the human capital method based on national average
income per capita and their losses of workdays.
In the outpatient phase, the Guidelines for Diagnosis and Treatment of Cervical Cancer,
issued by the Committee of Gynecological Oncology of the Chinese Anti-Cancer Association,
recommends patients to be regularly followed-up as outpatients every two months in the first
six-month period and every three months in the second six-month period after final discharge,
totaling five outpatient visits [19]. Thus, total costs during the outpatient phase were obtained
by multiplying the sum of the average direct medical and non-medical costs associated with
each outpatient visit by five.
To examine the quality of life impact of cervical cancer, responses to the EQ-5D descriptive
system for the current and worst health states were converted to health utilities using a China-
specific value set [20]. The baseline utility for patients at diagnosis was assumed to be the
norms for the Chinese population. The worst health states were expected to occur right after
the first inpatient treatments. The loss of QALY associated with cervical cancer from diagnosis
to the interview day was obtained by comparing different utilities at diagnosis, the worst health
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state, and the interview using the ‘under the curve’ method. Linear changes in EQ-5D scores
over time from diagnosis to the worst health state and from the worst health state to the inter-
view were assumed. The total QALY loss from diagnosis to one year after final discharge was
predicted based on results from the GLMs while controlling for time since diagnosis and the
full list of patient characteristics. Eventually, the average QALY loss per case by clinical stages
was obtained by averaging the corresponding predicted values.
In this study, the patient information was stored in coded encryption after data collection,
and we had no access to information that could identify individual participants. We adjusted
for inflation to match for 2018 US dollar value using a country-specific consumer price index
and foreign exchange rates [21]. All statistical analyses were performed using R version 3.6.1
for Windows.
2.4. Ethical considerations
The study was reviewed and approved by the institutional review board at Henan Cancer Hos-




From January 2017 to December 2018, there were a total of 4,169 inpatient admissions to the
Gynecology Department at the study hospital. Of these, 3,506 records of inpatient episodes
from 1,323 patients were eligible under the inclusion criteria. Among them, 844 patients had
experienced final discharge and 541 (40%) randomly selected patients were invited to the tele-
phone survey. Module completion rates varied from 26.1% (141/541) (the module on direct
costs for outpatient visits) to 61.0% (330/541) (the EQ-5D module). Main reasons for non-
completion included unwillingness to provide information, language barriers, and distrust of
investigators.
Table 1 describes patient characteristics. Overall, the majority of the patients were aged
above 45 years at diagnosis, living in rural areas, unemployed, and confirmed with less
advanced cervical cancer (IA-IIA). Generally, there were no significant differences between
patients who are involved in the analysis and those who are not. However, patients who
responded to the EQ-5D module had less advanced cancer compared to those who did not
(col. (6) of S1 Table). Stronger unwillingness to participate in the survey rather than higher
mortality among more advanced patients was responsible for this difference (S1 and S2 Tables
in the supplementary materials).
The distribution of inpatient phase duration among those who experienced final discharge
in our study shows that patients with advanced cancers generally underwent more extended
inpatient phases (see S1 Fig). For IA patients, their inpatient phase duration was around 23
days. In contrast, IB-III patients spent around 100 days and IV patients spent on average 147
days due to more rounds of chemotherapy.
3.2. Costs associated with cervical cancer per inpatient episode
For costs per inpatient episode, clinical stage and treatment methods were significantly associ-
ated with total costs, direct medical costs, and direct non-medical costs (col. (1)-(3) of
Table 2). Rural residence was also a strong predictor of higher direct non-medical costs (col.
(3) of Table 2). By contrast, older age was associated with lower indirect costs and those
employed paid higher indirect costs (col. (4) of Table 2).
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Table 1. Demographics, socioeconomic status, and clinical characteristics of patients involved in various stages of the study (n, %).














(1) (2) (3) (4) (5) (6)
Total 1323 (100) 844 (100) 225 (100) 141 (100) 158 (100) 330 (100)
Demographics
Age at diagnosis
<45 335 (25.3) 225 (26.7) 61 (27.1) 41 (29.1) 40 (25.3) 89 (27.0)
> = 45 988 (74.7) 619 (73.3) 164 (72.9) 100 (70.9) 118 (74.7) 241 (73.0)
Area of residence
Urban 334 (25.2) 219 (25.9) 52 (23.1) 33 (23.4) 39 (24.7) 85 (25.8)
Rural 989 (74.8) 625 (74.1) 173 (76.9) 108 (76.6) 119 (75.3) 245 (74.2)
Marital status
Married 1296 (98.0) 827 (98.0) 218 (96.9) 135 (95.7) 150 (94.9) 321 (97.3)
Unmarried 27 (2.0) 17 (2.0) 7 (3.1) 6 (4.3) 8 (5.1) 9 (2.7)
Socioeconomic status
Education level
Elementary 74 (32.9) 51 (36.2) 60 (38.0) 99 (30.0)
Junior school 84 (37.3) 51 (36.2) 53 (33.5) 119 (36.1)
High school 50 (22.2) 29 (20.5) 33 (20.9) 62 (18.8)
College 15 (6.7) 10 (7.1) 11 (7.0) 22 (6.7)
Unknown 2 (0.9) 0 (0) 1 (0.6) 28 (8.5)
Monthly family Income
(RMB)
< 5K 132 (58.7) 86 (61.0) 99 (62.7) 165 (50.0)
5K-10K 28 (12.4) 18 (12.8) 18 (11.4) 43 (13.0)
> 10K 17 (7.6) 10 (7.1) 11 (7.0) 24 (7.3)
Unknown 48 (21.3) 27 (19.1) 30 (18.9) 98 (29.7)
Insurance type
URBMI 36 (2.7) 21 (2.5) 7 (3.1) 2 (1.4) 3 (1.9) 11 (3.3)
UEBMI 139 (10.5) 92 (10.9) 25 (11.1) 18 (12.8) 18 (11.4) 33 (10.0)
NCMS 851 (64.3) 533 (63.2) 152 (67.6) 95 (67.4) 107 (67.7) 219 (66.4)
Others 58 (4.4) 36 (4.3) 6 (2.7) 4 (2.8) 7 (4.4) 13 (3.9)
No insurance 239 (18.1) 162 (19.2) 35 (15.5) 22 (15.6) 23 (14.6) 54 (16.4)
Employment status
Employed 496 (37.5) 315 (37.3) 79 (35.1) 50 (35.5) 56 (35.4) 116 (35.2)
Unemployed 827 (62.5) 529 (62.7) 146 (64.9) 91 (64.5) 102 (64.6) 214 (64.9)
Clinical characteristics
Clinical stage
IA 42 (3.2) 37 (4.4)) 11 (4.9) 8 (5.7) 7 (4.4) 15 (4.6)
IB 585 (44.2) 402 (47.6) 103 (45.7) 65 (46.0) 72 (45.5) 167 (50.6)
IIA 389 (29.4) 203 (24.1) 71 (31.6) 39 (27.6) 47 (29.7) 88 (26.7)
IIB 134 (10.1) 95 (11.3) 22 (9.8) 12 (8.5) 14 (8.9) 27 (8.2)
III 135 (10.2) 93 (11.0) 16 (7.1) 17 (12.0) 18 (11.3) 30 (9.1)
IV 38 (2.9) 14 (1.7) 2 (0.9) 0 (0.0) 0 (0.0) 3 (0.9)
Pathological type
Squamous cell 1113 (84.1) 734 (84.3) 199 (88.4) 125 (88.7) 140 (88.6) 279 (84.6)
Adenocarcinoma 127 (9.6) 84 (9.6) 15 (6.7) 9 (6.4) 9 (5.7) 33 (10.0)
(Continued)
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Fig 2 presents costs per inpatient episode (Panel A1) and the proportion of total costs by
components (Panel A2) across clinical stages. On average, total costs per inpatient episode
were $5,321, $4,589, $4,586, $13,084, $12,663, $4,143 for IA-IV patients, respectively. Com-
pared to patients of the other clinical stages, IIB and III patients spent almost two times more.
Across all clinical stages, direct medical costs accounted for the largest shares of total costs
(77.7%-84.7%), followed by indirect costs (9.2%-15.3%).
3.3. Costs per case from diagnosis to one year after discharge
Table 3 presents costs per case from diagnosis to one year after final discharge by clinical
stages. Direct medical costs during the inpatient phase and indirect costs increased with clini-
cal stages and were the top and the second largest components of total costs, with the exception
of IIB patients (Panel B2 of Fig 2). For IIB patients, indirect costs were slightly lower than
direct non-medical costs. Unfortunately, we were not able to obtain estimates on direct medi-
cal and non-medical costs for the outpatient phase for IV patients (col. (2) and (4) of Table 3).
Only a small number of IV patients were admitted and none of the IV patients who we invited
for the telephone interview completed the modules regarding direct medical and non-medical
costs associated with outpatient visits. Since estimates on the direct medical costs and direct
non-medical costs during the outpatient phase did not vary much across clinical stages, we
assumed that the values for IV patients were the same as those for III patients. On average,
total costs per cervical cancer patient from diagnosis to one year after final discharge were
$8,066, $15,260, $18,873, $16,630, $19,440, $22,888 for IA-IV patients, respectively.
3.4. QALY loss per case
The EQ-5D scores of the descriptive system and VAS suggest similar patterns. Compared to
the norms of the Chinese population, cervical cancer patients had poorer health states (S3
Table). The average total QALY loss for a cervical cancer patient from diagnosis to one year
after final discharge was 0.054, 0.167, 0.230, 0.205, 0.257 and 0.190 for clinical stages of IA-IV,
respectively (col. (7) of Table 3).
4. Discussion
4.1. Principal findings
This study adopted a societal perspective and examined clinical stage specific costs and QALY
loss associated with cervical cancer from diagnosis to one year after final discharge in Henan
Province, China. Based on the inpatient records from the largest cancer hospital in the
Table 1. (Continued)














(1) (2) (3) (4) (5) (6)
Other 26 (2.0) 16 (1.8) 4 (1.8) 3 (2.1) 3 (1.9) 5 (1.5)
Unknown 57 (4.3) 37 (4.2) 7 (3.1) 4 (2.8) 6 (3.8) 13 (3.9)
The table presents patient counts and percentages out of total for each group demographic and clinical characteristics across all analytical steps. URBMI stands for
Urban Resident Basic Medical Insurance, UEBMI for Urban Employee Basic Medical Insurance, and NCMS for New Cooperative Medical Scheme.
https://doi.org/10.1371/journal.pone.0232129.t001
PLOS ONE The economic burden of cervical cancer in Henan Province, China: A retrospective study
PLOS ONE | https://doi.org/10.1371/journal.pone.0232129 May 7, 2020 8 / 14
province and a retrospective telephone survey, we found that costs per case ranged from
$8,066-$22,888 and QALY loss ranged from 0.05–0.26.
To further understand the financial burden, we calculated the average time from diagnosis
to one year after final discharge by clinical stages. We then divided total costs per case by these
Table 2. Statistically significant predictors of costs per inpatient episode (US$) (coefficients, confidence interval).
Costs per inpatient episode
Total Direct medical Direct non-medical Indirect
(1) (2) (3) (4)
Age at first diagnosis (reference group: < 45)
> = 45 ─ ─ ─ -2445.5���
─ ─ ─ (-3359.1, -1531.9)
Area of residence (reference group: urban)
Rural ─ ─ 1579.7��� ─
─ ─ (957.2, 2202.1) ─
Employment status (reference group: unemployed)
Employed ─ ─ 979.1�
─ ─ (118.0, 1840.1)
Clinical stage (reference group: IA)
IB 5970 4382.0 1355.9 ─
(-801.6, 12741.5) (-939.5, 9703.5) (-442.1, 3153.8) ─
IIA 6538 6017.3� 1020.3 ─
(-308.0, 13383.1) (637.6, 11396.9) (-803.8, 2844.4) ─
IIB 13708�� 14304.5��� 3761.4�� ─
(5155.4, 22260.6) (7583.4, 21025.6) (1490.8, 6032.0) ─
III 25060��� 22691.9��� 3212.7�� ─
(16661.1, 33457.9) (16091.9, 29291.8) (983.1, 5442.3) ─
IV 7584 7530.0 724.1 ─
(-3019.4, 18187.8) (-803.0, 15862.9) (-2095.1, 3543.3) ─
Treatment methods (reference group: surgery)
Chemotherapy -25883��� -22827.5��� -867.2�� -2578.3���
(-28114.8, -23651.5) (-24581.3, -21073.7) (-1460.3, -274.2) (-3520.8, -1635.9)
Radiotherapy 30507��� 27014.5��� -1460 3907.3��
(23765.1, 37248.3) (21716.6, 32312.5) (-3249.7, 329.6) (1074.9, 6739.7)
Surgery and chemo combo 11754�� 7100.6� 248.2 4520.8��
(4670.0 18808.8) 1556.9, 12644.4) (-1628.2, 2124.5) (1439.0, 7602.5)
Radio and chemo combo 47640��� 35564.1��� 1887.4��� 9363.0���
(44222.1, 51058.2) (32878.0, 38250.2) (979.7, 2795.1) (8019.1, 10706.8)
Surgery, radio and chemo combo 77726��� 72625.3��� -3146.3 2506.2
(61554.7, 93896.5) (59917.2, 85333.4) (-7440.6, 1148.0) (-4215.2, 9227.6)
Sample size 575 575 575 575
Results were produced from participants who successfully answered questions regarding inpatient episodes. For each costs category, patient characteristics with p-value
above 0.10 in univariate analyses were excluded and the final model specification was selected according to minimum Akaike information criterion (AIC) stepwise
regression procedure.
� for significant at the 5% level
�� for significant at the 1% level
��� for significant at the 0.1% level.
https://doi.org/10.1371/journal.pone.0232129.t002
PLOS ONE The economic burden of cervical cancer in Henan Province, China: A retrospective study
PLOS ONE | https://doi.org/10.1371/journal.pone.0232129 May 7, 2020 9 / 14
time estimates. The overall average was weighted by the proportion of each clinical stage
admitted to the study hospital. We found that the average annual costs per cervical cancer
patient were 1.7 times GDP per capita and 4.0 times per capita household disposable income
in Henan Province as of 2018. According to a recent systematic review, patients in middle-
and high-income countries only spend 75.52% and 30.12% of the local GDP per capita on cer-
vical cancer treatment [22]. Our results suggest that from the societal perspective, the eco-
nomic burden of cervical cancer in Henan province is much higher than these countries.
Fig 2. Costs per inpatient episodes and costs per case from diagnosis to final discharge, by clinical stages. Costs per inpatient episode were described in panel A1.
The proportion of costs per inpatient episode by components was presented in panel A2. Costs per case from diagnosis to final discharge were described in panel B1.
The proportion of costs per inpatient episode by components was presented in panel B2. Values presented in the figure were rounded to one digit decimal place.
https://doi.org/10.1371/journal.pone.0232129.g002
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4.2. Comparison with other studies
Previous studies from China mainly focused on total direct medical expenditures during the
inpatient phase [23] or the average medical expenditures associated with inpatient episodes
[24–28]. To support comparison with existing studies, we also produced these results. Based
on a national sample of cervical cancer patients, Tao et al. estimated that the direct economic
burden associated with hospitalization in Chinese cities was $7,706 for patients at early stages
(IA-IIA) and $13,319 for patients at advanced stages (IIB-IV) (results adjusted to US dollar in
2018) [23]. In contrast, our study produced larger estimates mainly because our calculation
was based on patients who have completed the entire inpatient phase of their treatment pro-
cess rather than all patients admitted to hospitals during a given period. We noted that costs
estimates for patients could be inaccurate if the entire treatment process was not fully
recognized.
Although previous studies that reported expenditures per inpatient episode were conducted
in different areas of China [24–28], we found similar results that clinical stages and treatment
methods were important predictors of direct medical costs associated with hospitalization (col.
(2) of Table 2).Moreover, we found that direct non-medical costs of hospitalization were
higher among rural residents due to larger travel costs (col. (3) of Table 2). Indirect costs were
higher among the employed due to higher income loss (col. (4) of Table 2).
Our study contributed to the existing literature on the economic burden of cervical cancer
in China due to a number of features. First, our estimates suffer less under-estimation because
we accounted for a wide range of costs categories and considered the entire inpatient phase
and a one-year outpatient phase. We highlighted the importance of indirect costs and costs
during the outpatient phase as a component of financial burden, which makes up 9.4%-15.2%
and 9.1%-29.0% of total costs (Table 3, Panel B2 of Fig 2). Second, we provided more detailed
estimates for each clinical stage rather than broadly categorized patients into early stages and
advanced stages. Third, we estimated QALY loss from diagnosis to one year after final dis-
charge, which is an important parameter for cost-effectiveness analyses on interventions
against cervical cancer. Fourth, our study was based on a large sample of cervical cancer
patients and inpatient records, which added to the accuracy of our results.
4.3. Policy implications
This study speaks to the important policy concern on whether it is cost-effective for the central
government of China to add the HPV vaccine into its national immunization program.
Table 3. Costs and loss in quality-adjusted life years per case from diagnosis to one year after final discharge, by clinical stages (US$).
Direct medical costs Direct non-medical costs Indirect costs Total costs QALY loss
Inpatient phase Outpatient phase Inpatient phase Outpatient phase
(1) (2) (3) (4) (5) (6) (7)
Clinical stage
IA 4747 1832 163 510 814 8066 0.05
IB 9827 1649 1050 409 2325 15260 0.17
IIA 13799 1405 1152 437 2080 18873 0.23
IIB 12263 1272 1049 487 1559 16630 0.21
III 14417 1669 1014 408 1933 19440 0.26
IV� 17617 1669 571 408 2623 22888 0.19
�Values for III patients were used for columns (2) and (4). Total costs in column (6) were calculated accordingly.
https://doi.org/10.1371/journal.pone.0232129.t003
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Currently, HPV vaccines in the China market are produced by two foreign pharmaceuticals
(GlaxoSmithKline and Merk & Co.) and injection costs are fully borne by individuals.
Although the average annual costs per cervical patient were estimated to be 4.0 times per capita
household disposable income in Henan Province, the costs of three doses of HPV vaccine are
also expensive to afford (3.3%-10.4% of per capita household disposable income). In January
2020, a newly approved domestic bivalent HPV vaccine is being prepared for production. It is
priced at nearly half of the costs of those provided by foreign drugmakers, which potentially
increases the cost-effectiveness of the injection.
Unfortunately, previous study on the economic burden of cervical cancer in China did not
fully recognize the long and complicated treatment process of the disease, leading to an under-
estimation of the costs incurred to the whole society that HPV vaccines can prevent. Our study
instead produced more accurate estimates for the treatment costs of cervical cancer and loss in
quality-adjusted life years associated with the disease. These results provided crucial parame-
ters for cost-effectiveness studies and are important for the decision of relevant immunization
policy.
4.4. Limitations
Our study is subject to several limitations. First, information collected from the telephone sur-
veys may be subject to recall bias. Information on non-medical and indirect costs may suffer
measurement errors since it was obtained based on the memory of the participants. Second,
the response rate of the telephone survey was not ideal which may potentially affect the accu-
racy of our results. Comparisons between patients in the final analysis and those not (S1 and
S2 Tables) suggested no overall significant differences in their characteristics. However, results
for IV patients might be less accurate due to the limited number of patients who provided
answers during the survey. Third, we used the norms as the health states for patients at diagno-
sis, which, however, could lead to over-estimation. And we assumed that the worst health
states occurred on the day of the first treatment, which may be less valid for patients who did
not make a good recovery. Fourth, due to lack of data, we did not consider impacts of early
mortality associated with cervical cancer in our analysis. Impacts of long-term consequences
could be a direction of future studies. Fifth, the disease burden of cervical cancer varies sub-
stantially across areas with different levels of development in China. To provide more informa-
tive parameters for cost-effectiveness analysis, area-specific costs estimates are also important,
which could be the focus of future studies.
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